Aims a-Melanocyte-stimulating hormone (a-MSH), derived from the precursor molecule pro-opiomelanocortin, exerts potent anti-inflammatory actions in the vasculature, but its role in circulatory regulation remains unclear. Therefore, we sought to investigate whether a-MSH could regulate the local control of blood vessel tone.
Introduction
The melanocortin peptides, which include adrenocorticotropic hormone (ACTH) and a-, b-, and g-melanocyte-stimulating hormones (MSH), are derived from a common precursor protein pro-opiomelanocortin (POMC). Melanocortins have well-established roles in the central regulation of energy homeostasis and cardiovascular functions, and mounting evidence demonstrates that they are also implicated in the control of inflammation. 1, 2 They exert their biological actions through a family of five related G-protein coupled melanocortin receptors (MC1-MC5). 3 The MC1 receptor, predominantly expressed in peripheral tissues, is the classic MC receptor capable of binding a-MSH with high affinity and mediating melanin dispersion in melanocytes. 4, 5 MC1 receptors are also abundant in cells of the immune system where they mediate anti-inflammatory effects of a-MSH. 6 -8 Several recent studies have reported that endothelial cells of humans and rodents express MC1 receptors, as well as POMC, and seem to be capable of processing POMC into biologically active a-MSH. 9 -11 Although endothelial MC1 receptors have been investigated as anti-inflammatory targets, it is unexplored whether they could regulate the endothelium-dependent control of blood vessel tone.
The vascular endothelium plays a crucial role in the regulation of vascular tone by releasing several vasoactive substances, thereby adjusting regional blood flow in response to tissue demands. 12, 13 Nitric oxide (NO) produced by endothelial NO synthase (eNOS) upon shear stress and receptor activation is particularly important for the maintenance of vascular homeostasis. It relaxes vascular smooth muscle cells by activating guanylyl cyclase and increasing cGMP production. 14 However, the importance of NO in vascular physiology is not solely determined by its direct vasodilating properties. It contributes to vascular homeostasis also by inhibiting vasoconstrictor influences, platelet aggregation, and proliferation of vascular smooth muscle cells. 15, 16 Owing to the multifaceted role of endothelium-derived NO, impairment of its availability is a predisposing and underlying factor for major cardiovascular disease states.
Along with the evident expression of MC1-R in the endothelium, we were inspired by an interesting clinical observation: a stable analogue of a-MSH, NDP-a-MSH (also known as afamelanotide or MT-I), 17 currently investigated and developed for the treatment of skin diseases, was reported to cause headache and flushing as predominant side effects, 18 typical reactions that are associated with vasodilatation. Given this, we hypothesized that a-MSH by interacting with the endothelial MC1-R might have a role as a regulator of vascular function. Here we identify that a-MSH promotes endotheliumdependent control of blood vessel tone by enhancing signalling through the NO-cGMP pathway. This is attributed to activation of eNOS mediated by endothelial MC1 receptors. These findings suggest that peripherally acting a-MSH analogues might represent a new therapeutic approach for the control of endothelial dysfunction in cardiovascular disease.
Methods
Full details of the methods used in this study are given in the online Supplementary material.
Mice and treatments
All animal studies were approved by the national Animal Experiment Board in Finland and conducted in accordance with the Directive 2010/ 63/EU of the European Parliament. To study acute and chronic effects of melanocortins, we administered NDP-a-MSH (0.3 mg/kg, i.p., 18 h before sacrifice) to 10-month-old and MT-II (0.3 mg/kg/day, i.p., for 3 weeks) to diet-induced obese C57Bl/6N mice. 19 As a genetic model of chronic melanocortin activation, we studied transgenic mice overexpressing a-MSH under the universal CMV promoter (C57BL/6J-A wJ background after eight backcrosses). 20 Mice were euthanized via CO 2 asphyxiation and the selected blood vessels were harvested and used for ex vivo experimentation.
Vascular reactivity analysis
Segments (2 mm in length) of mouse thoracic aortae and small mesenteric arteries (80 -100 mm in diameter) were studied by wire myography for contractile responses to phenylephrine (PE), and endothelium-dependent and -independent relaxations to acetylcholine (ACh) and sodium nitroprusside (SNP), respectively. After mounting, vessels were equilibrated, normalized, and contracted repeatedly with 62 mmol/L KCl until maximal and reproducible contractions were obtained. 21, 22 To measure vasodilatation, arterial rings were pre-contracted with prostaglandin F 2a (aorta) or PE (mesenteric artery) and the contraction was adjusted to 50 -80% of the reference contraction to 62 mmol/L KCl. 23 Effects of NOS blockade on vascular responses were tested by applying L-NNA (100 mmol/L for 30 min).
NO release and NOS activity assay
NO (nitrate + nitrite, NO x ) concentrations in cell-culture medium were determined by fluorometric detection (Cayman Chemicals). Aortic samples were homogenized in 25 mM Tris-HCl and incubated at room temperature for 60 min in the presence of calmodulin (0.1 mM), NADPH (1.2 mM), and CaCl 2 (0.7 mM) according to the manufacturer's instructions (Cayman Chemicals). The NO synthesizing activity was determined by quantifying the rate of the conversion of [ 3 H]l-arginine to [ 3 H]l-citrulline. NOS activity is expressed as dissociations per minute per mg protein.
cGMP content of aortic rings
Aortic segments were equilibrated (378C, 30 min) in Krebs bicarbonate buffer and then treated with NDP-a-MSH (1 mmol/L) for 60 min. The tissue samples were homogenized in 5% trichloroacetic acid and assayed for cGMP content with an enzyme immunoassay (Cayman Chemicals). The cGMP levels of equilibrated, untreated rings were taken as the control.
Echocardiography
For Doppler echocardiography, mice were anaesthetized with isoflurane (induction 3%, maintenance 1.5%) and assigned to scanning with an Acuson Sequoia C512 instrument equipped with a 15 MHz linear transducer 15L8 (Siemens Acuson). Diastolic peak and mean flow velocities in the middle left coronary artery were recorded under colour Doppler guidance during baseline (1.5% isoflurane) and hyperaemic flow conditions (2.5% isoflurane). 24, 25 Coronary flow reserve (CFR) was calculated as the ratio of hyperaemic to baseline flow velocity. All measurements were done off-line in a blinded manner.
Isolated heart perfusion and coronary flow
Mice were anaesthetized with pentobarbital sodium (50-100 mg/kg) and administered intravenous heparin (0.2 mL of 1000 IU/mL). Pedal and tail withdrawal reflexes were monitored to ensure adequate depth of anaesthesia. Thereafter, the heart was isolated, mounted according to the Langendorff method and retrogradely perfused through the aorta at a constant pressure (60 mmHg) with Krebs bicarbonate buffer. After equilibration, coronary vasodilator responses to ACh and bradykinin were assessed by timed collection of the outflow perfusate. After the experiments, the hearts were weighed and coronary vasodilator responses were expressed as increase in mL/min/g of wet tissue weight.
Cell culture
Primary human endothelial cells (HUVEC) were isolated from freshly collected umbilical cords. 26 The protocol for preparing a primary human cell culture was approved by The Joint Ethics Committee of Turku University and Turku University Central Hospital, and conforms with the principles outlined in the Declaration of Helsinki. HUVECs and transformed HUVEC-derived endothelial cells (EA.hy926) were incubated in complete medium (M199 and DMEM, respectively) supplemented with 10% FBS. After confluence, cells were stimulated as indicated in the graph legends and used for mRNA and protein analyses.
Quantitative RT -PCR and western blotting
Total RNA from cell-culture samples was extracted (Qiagen) and reversetranscribed (Applied Biosystems). Quantitative RT -PCR was performed using SYBR Green protocols (Kapa Biosystems) on an Applied Biosystems 7300 Real-Time PCR system. Samples were run in triplicate. Primer sequences are given in Supplementary material online, Tables S1 and S2. mRNA expression levels were normalized to glyceraldehyde-3-phosphate a-MSH, NO, and endothelial function dehydrogenase (GAPDH) using the comparative DCt method and are presented as relative transcript levels (2 2DDCt ).
Western blot analysis
Cell-culture samples were lysed in RIPA buffer supplemented with a protease and phosphatase inhibitor cocktail (Thermo Scientific). Aliquots of total protein were size-fractioned by SDS -PAGE and transferred onto nitrocellulose membranes. Membranes were probed with specific antibodies for eNOS, phospho(Ser 1177 )-eNOS and Mn-SOD (BD Biosciences). The results for total protein expression were normalized to b-actin (Sigma) to correct for loading.
Chemicals
The selective MC1-R antagonist MSG606 was synthesized as previously described. 27 All other drugs and reagents were purchased from Sigma-Aldrich except PGF 2a and U46619 which were from Cayman Chemicals.
Statistical analyses
All data are expressed as means + SEM. Differences between two groups were analysed by unpaired Student's t-test. Comparisons between three or more groups were made by one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc tests. For two independent factors, two-way ANOVA was used. Concentration-response curves were generated using nonlinear regression and E max and EC 50 values were compared using the extra sum-of-squares F-test. A two-tailed P-value of ,0.05 was considered statistically significant.
Results

a-MSH enhances endothelium-dependent vasodilatation without directly relaxing blood vessels
To test the hypothesis that melanocortins regulate endotheliumdependent control of blood vessel tone, isolated rings of the mouse aorta and small mesenteric arteries were studied by wire myography for vascular reactivity. First, we investigated whether NDP-a-MSH could directly modulate vascular tone of isolated arteries, and applied NDP-a-MSH to pre-constricted mouse aortae or mesenteric arteries. We observed, however, no vasoconstriction or vasorelaxation in mouse aortae or mesenteric arteries ( Figure 1A) . Next, to determine whether a-MSH could modulate endothelial function, we pre-treated isolated arteries with NDP-a-MSH (1 mmol/L) for 60 min and assessed the responses to endothelium-dependent vasodilatation. In vitro pre-treatment with NDP-a-MSH significantly enhanced aortic responses to acetylcholine (ACh) ( Figure 1B) . These responses were confined to large arteries as the same pretreatment failed to improve ACh responses in mesenteric arteries ( Figure 1C ). NOS inhibition with L-NNA abrogated ACh-evoked relaxation and the effect of NDP-a-MSH on the ACh-responses ( Figure 1D) , implying that increased NO formation contributes to the improved endothelium-dependent relaxation. Consistently, NOS activity tended (P ¼ 0.07) to be increased and cGMP level was markedly enhanced in NDP-a-MSH-treated aortae ( Figure 1E and F ). In addition, NDP-a-MSH treatment increased the sensitivity of the vascular smooth-muscle layer to endothelium-independent relaxation evoked by the NO donor SNP ( Figure 1G ). Collectively, a-MSH seems to be devoid of direct effects on blood vessel tone, but it substantially enhances NO-dependent endothelial function and endotheliumindependent vasorelaxation.
3.2
In vivo treatment with a-MSH analogues ameliorates endothelial dysfunction in aged and obese mice To further examine the vascular effects of melanocortins, we subjected 10-month-old C57Bl/6N mice to acute (0.3 mg/kg, 18 h before sacrifice) treatment with NDP-a-MSH and diet-induced obese (DIO) mice to chronic (0.3 mg/kg/day, for 3 weeks) treatment with a more stable analogue of a-MSH, MT-II, to obtain extended duration of action. With the selected dosage regimen, MT-II had no effect on body weight or adiposity of DIO mice (see Supplementary material online, Table S3 ). As a genetic model of chronic melanocortin activation, we studied 5-month-old transgenic MSH-OE mice overexpressing a-MSH. Aged and obese mice were selected for the pharmacological interventions based on our initial findings showing that melanocortins enhance endothelial function. Hence, we sought to investigate whether melanocortins could ameliorate the endothelial dysfunction present in these mice (see Supplementary material online, Figure S1 ).
To evaluate vascular function in melanocortin-treated and MSH-OE mice, isolated rings of the aorta and mesenteric arteries were first studied for contractile responses to PE. Acute administration of NDP-a-MSH had no effect on PE-induced vasoconstriction (Figure 2A and Supplementary material online, Table S4 ). However, the maximal vasoconstriction induced by PE was significantly smaller in the aorta of MSH-OE mice compared with wild-type (WT) control mice ( Figure 2C and Supplementary material online, Table  S4 ), and a similar trend (P ¼ 0.07) was observed in MT-II-treated Figure 2B and Supplementary material online, Table S4 ). In contrast, in small mesenteric arteries, the maximum contractile response was unaffected by melanocortins (see Supplementary material online, Figure S2 ). Pre-treatment with the NOS inhibitor L-NNA substantially augmented the aortic contractile responses and abolished the differences in the maximum response to PE between the MSH and control groups (Figure 2E and F ) .
Next, we monitored endothelium-dependent relaxation to ACh and observed that acute and chronic melanocortin administration improved relaxation responses to ACh in the aorta of 10-month-old mice and DIO-mice ( Figure 2G and H ) . MSH-OE mice showed no distinct increment in the maximum response to ACh ( Figure 2I ). However, a tendency (P ¼ 0.06) towards increased sensitivity (EC 50 ) to ACh-evoked relaxation was observed in the aorta of MSH-OE mice. NOS inhibition with L-NNA significantly attenuated relaxation responses to ACh and eliminated the effect of melanocortin administration on the ACh-responses ( Figure 2G and H ) . The enhancements in NO-driven relaxation occurred without apparent differences in eNOS protein levels (see Supplementary material online, Figure S3 ). In contrast to the findings in the aorta, melanocortins were again incapable of enhancing ACh-responses of small mesenteric arteries (see Supplementary material online, Figure S2 ).
In addition to improving endothelium-dependent relaxation in the aorta, chronic MT-II treatment and MSH-OE increased endotheliumindependent vasodilatation evoked by SNP. This effect was observed in the aorta and small mesenteric arteries ( Figure 3A-D ).
Melanocortins contribute to coronary flow regulation
Having identified novel effects of a-MSH on the function of isolated vessels, we next investigated whether similar effects appear also in an intact coronary circulation. We assessed coronary vascular function in Langendorff-perfused hearts from saline-and NDP-a-MSHtreated mice. Vasodilator responses to endothelium-dependent agonists were studied by measuring increases in coronary outflow. Responses to ACh were comparable between the groups while bradykinin induced significantly greater vasorelaxation and consequent increase in total coronary flow in the hearts of NDP-a-MSHtreated mice (Figure 4A and B) .
To obtain complementary in vivo evidence, we evaluated the CFR of MSH-OE mice by applying Doppler echocardiography. We found that CFR was increased in 3-month-old as well as in 6-month-old MSH-OE mice compared with age-matched WT control mice ( Figure 4C) . These results, derived from different methods and models, together underscore that melanocortins contribute not only to vascular function of isolated peripheral arteries but also to coronary flow regulation.
Activation of endothelial MC1 receptors by a-MSH regulates NO availability
To investigate the mechanism whereby a-MSH improves endothelial function, we used cultured primary (HUVEC) and transformed (EA.hy926) human endothelial cells. First, we were able to confirm that human endothelial cells exclusively express the MC1 receptor subtype (see Supplementary material online, Table S5 ). MC1-R expression was also found in the mouse aorta (see Supplementary material online, Table S5 ). Next, we examined the effects of NDP-a-MSH on eNOS expression and phosphorylation, central factors affecting NO production. Stimulation with NDP-a-MSH for 4 h elicited a dose-dependent increase in eNOS mRNA expression ( Figure 5A) , which then seemed to be downregulated after 18 h stimulation ( Figure 5B) . These changes in mRNA expression were translated into a tendency (P ¼ 0.07) of increased eNOS protein levels after 18 h treatment with 1 mmol/L NDP-a-MSH ( Figure 5C ). To address the role of the MC1-R as a mediator of these responses, we tested whether the observed effects were reversed by the selective MC1-R antagonist MSG606. Indeed, MC1-R antagonism abolished the stimulatory effects of NDP-a-MSH on eNOS expression ( Figure 5B and C ) . Since NDP-a-MSH enhanced NO production of endothelial cells in a relatively short time scale ( Figure 3D) , we investigated whether it regulates post-translational activation of eNOS. NDP-a-MSH time-dependently ( Figure 5E ) and through the MC1-R ( Figure 5F ) stimulated phosphorylation of eNOS at Ser 1177 , which is critical for its enzymatic activity.
Next, we investigated the effects of NDP-a-MSH on mRNA expression of the antioxidant enzymes catalase, glutathione peroxidase (GPx1), and mitochondrial superoxide dismutase (Mn-SOD) in (Figure 6E-G) . We found that NDP-a-MSH selectively increased the expression of Mn-SOD ( Figure 6G) , an enzyme responsible for the neutralization of superoxide anions to oxygen and hydrogen peroxide. This effect, mediated by the MC1-R, was also observed at the protein level ( Figure 6H) . Taken together, our results demonstrate that a-MSH, by binding to endothelial MC1-R, regulates the eNOS system at the transcriptional and post-translational levels and increases Mn-SOD expression.
Discussion
Our study uncovers a peripheral melanocortin signalling pathway that contributes to the regulation of blood vessel tone in a favourable manner, thus promoting vascular health. First, we show that a-MSH augments vascular relaxation via enhancing NO-cGMP-dependent responses. Secondly, our results establish a mechanistic link between the endothelial MC1 receptor and a-MSH-mediated regulation of NO availability. Owing to the beneficial effects in vascular physiology, endothelial MC1 receptors might represent a new therapeutic target for vascular protection in cardiovascular disease such as hypertension and atherosclerosis.
To the best of our knowledge, this is the first study demonstrating a peripheral site of action for a-MSH in circulatory regulation. Haemodynamic effects of peripherally administered MSH peptides have been widely investigated, but their effects have been linked to central mechanisms and to g-MSH instead of a-MSH. 28, 29 Interestingly, two early studies reported that i.v. injections of a-MSH increased tissue blood flow in cats and sheep, but the mechanisms whereby a-MSH exerted this action remained unknown. 30, 31 Consistent with these early findings, our results suggest that a-MSH could increase tissue blood flow by affecting the local control of vascular tone. Although a-MSH had no immediate effects on vascular tone, we observed that it improves endothelial function via augmenting NO availability. This, in turn, has indirect effects on vascular tone as it blunts vasoconstrictor influences and enhances endothelium-dependent vasodilatation.
We noted that a-MSH elicited vessel-size-dependent improvements in endothelium-mediated vasodilatation through enhanced NO formation. The endothelial NOS system has variable significance in different parts of the circulatory system, since vascular tone of large arteries is known to be more strongly dependent on the function of eNOS than that of small arteries. 32, 33 Accordingly, the relative importance of NO for ACh-induced relaxation increases as the vessel size increases, thereby explaining why the a-MSH-stimulated effects on endothelium-dependent relaxation were confined to large arteries. Furthermore, a-MSH attenuated responses to PE in the aorta and this effect was eliminated by inhibiting the activity of NOS, indicating that a-MSH blunts vasoconstrictor influences through enhanced NO release. The beneficial influence of a-MSH appeared not only in endothelial capacity for NO formation but also in vascular sensitivity to SNP-induced vasodilatation. This effect was apparent in the aorta and small mesenteric arteries alike, indicating improved signalling downstream of NO, regardless of the vessel size. However, the underlying mechanism for this improvement remains largely unclear. Based on the finding of improved endothelium-independent vasodilatation, it will be intriguing to investigate whether MC receptors are also expressed in vascular smooth muscle cells and if so, whether they could regulate downstream effectors of NO such as guanylyl cyclase.
In addition to improving the function of peripheral arteries, melanocortins showed promising effects on coronary flow regulation. In vivo treatment with NDP-a-MSH increased coronary flow response to bradykinin in the isolated heart. This observation could be attributed to increased NO production, because in mice, responses to bradykinin in the intact coronary circulation are predominantly NOdependent. 34 The finding that ACh-induced coronary flow response was unaffected by NDP-a-MSH-treatment supports this notion, since ACh increases coronary flow in the mouse heart primarily via endothelial prostacyclin formation. 35 Furthermore, long-term melanocortin activation in MSH-OE mice was associated with improved flow reserve of epicardial coronary arteries. Taken together, the present findings provide conclusive evidence that a-MSH has wide-ranging effects in promoting endothelium-dependent and -independent blood vessel relaxation and is able to ameliorate endothelial dysfunction associated with ageing and diet-induced obesity independent of its well-established effects on metabolic regulation.
To shed light on the underlying mechanisms, we used cultured human endothelial cells and were able to show that a-MSH regulates NO availability through endothelial MC1 receptors. NO availability can be increased by enhancing NO production via transcriptional and post-translational activation of eNOS, and by reducing ROS- mediated breakdown of NO. 36 -38 We demonstrated that analogues of a-MSH have potential, at least in vitro, to engage all of these mechanisms to increase NO availability. a-MSH activated eNOS through transcriptional regulation and post-translational phosphorylation. Furthermore, endothelial MC1 receptors have the capacity to regulate Mn-SOD expression. All of these effects, separately and in concert with each other, are likely to enhance the local availability of NO in blood vessels, supporting the findings from vascular function measurements. Our in vitro findings are in good agreement with a recent study showing that NDP-a-MSH administration increased the expression of eNOS and Mn-SOD in the basilar artery of the rat brain. 39 However, although the present results show that a-MSH increased eNOS expression in cultured endothelial cells, in vivo treatments promoted NO-dependent relaxations without changes in eNOS expression, indicating that increased NO availability is primarily attributed to other mechanisms such as eNOS phosphorylation. Beyond these molecular underpinnings, the present observations merit further research to dissect the involved intracellular signalling pathways and the correspondence of the molecular-level effects with physiological functions.
In conclusion, our results show that a-MSH has significant effects on the control of blood vessel tone by enhancing NO-cGMPdependent relaxation responses through endothelial MC1 receptors. Vascular dysfunction and particularly impairment in endotheliumdependent vasodilation are early markers of many cardiovascular disease states. Endothelial dysfunction is characterized by reductions in eNOS activity and vascular NO availability. Furthermore, inflammation plays a key role and is likely to contribute to the development of endothelial dysfunction. In these respects, a-MSH analogues could have therapeutic value in cardiovascular disease through their ability to promote endothelial function combined with their known antiinflammatory actions in the vasculature. Now, considering that there is unmet medical need to develop novel therapies to restore endothelial function, it would be worthwhile to further investigate whether a-MSH-based treatments could translate into therapeutic efficacy in severe pathological conditions such as atherosclerosis.
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